11 results match your criteria: "Italy (G.M.D.F.); National Institute of Cardiology[Affiliation]"
Mixed Shock Complicating Cardiogenic Shock: Frequency, Predictors, and Clinical Outcomes.
Circ Heart Fail
July 2024
Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy (L.B., G.F., A.C., V.R., B.P., L.C., M.G., V.P., S.S., F.C., S.A., A.M.S.).
Article Synopsis
- * In a study of 200 patients with pure CS, 24.5% developed MS, with lower blood pressure, liver damage, and suspected infection identified as independent predictors of its occurrence.
- * MS is associated with higher in-hospital mortality (53.1% vs. 27.8%) and longer hospital stays, while using temporary mechanical support can reduce the chances of death for affected patients.
Asymptomatic Patients With Brugada ECG Pattern: Long-Term Prognosis From a Large Prospective Study.
Circulation
November 2023
Division of Cardiology, Policlinico Casilino, Rome, Italy (A.M., E.S., C.C., S.C., M.D.M., L.C.).
Article Synopsis
- Brugada syndrome presents management difficulties, especially for asymptomatic patients with the Brugada ECG pattern, and this study aimed to analyze the long-term outcomes of a large group of these individuals.
- A total of 1,149 asymptomatic patients with Brugada ECG were monitored over 2 to 22 years, revealing an overall low annual arrhythmic event rate of 0.2%, with slightly higher risks observed in those with spontaneous type-1 Brugada ECG.
- The findings suggest that asymptomatic patients generally have a low risk of serious cardiac events, highlighting the need for careful monitoring and potential individual risk assessments rather than a one-size-fits-all approach.
Clinical governance of patients with acute coronary syndromes.
Eur Heart J Acute Cardiovasc Care
November 2022
Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Italy.
Aims: Using the principles of clinical governance, a patient-centred approach intended to promote holistic quality improvement, we designed a prospective, multicentre study in patients with acute coronary syndrome (ACS). We aimed to verify and quantify consecutive inclusion and describe relative and absolute effects of indicators of quality for diagnosis and therapy.
Methods And Results: Administrative codes for invasive coronary angiography and acute myocardial infarction were used to estimate the ACS universe.
Incessant Pericarditis as a Risk Factor for Complicated Pericarditis and Hospital Admission.
Circulation
January 2021
University Cardiology (M.I., A.A., C.S., C.G., G.M.D.F.), Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Impact of Kissing Balloon in Patients Treated With Ultrathin Stents for Left Main Lesions and Bifurcations: An Analysis From the RAIN-CARDIOGROUP VII Study.
Circ Cardiovasc Interv
March 2020
Division of Cardiology, Department of Medical Science, Città della Salute e della Scienza, Turin (F.D., A.S., F.F., A. Montefusco, G.d.L., F.B., P.O., M.R., F.C., M.D., G.M.D.F.).
Background: There are limited data regarding the impact of final kissing balloon (FKI) in patients treated with percutaneous coronary intervention using ultrathin stents in left main or bifurcations.
Methods: All patients undergoing left main or bifurcations percutaneous coronary intervention enrolled in the RAIN registry (Very Thin Stents for Patients With MAIN or BiF in Real Life: The RAIN, a Multicenter Study) evaluating ultrathin stents were included. Major adverse cardiac event (a composite of all-cause death, myocardial infarction, target lesion revascularization, and stent thrombosis) was the primary end point, while its components, along with target vessel revascularization, were the secondary end points.
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Circulation
August 2018
Oslo University Hospital, Ulleval and Medical Faculty, University of Oslo, Norway (T.R.P.).
Background: The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab significantly reduced major vascular events in patients with stable atherosclerotic cardiovascular disease, including patients with prior myocardial infarction (MI). Within the broad group of patients with prior MI, we hypothesized that readily ascertainable features would identify subsets who derive greater clinical risk reduction with evolocumab.
Methods: The 22 351 patients with a prior MI were characterized on the basis of time from most recent MI, number of prior MIs, and presence of residual multivessel coronary artery disease (≥40% stenosis in ≥2 large vessels).
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Circulation
July 2016
From the TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (E.A.B., M.P.B., E.B., P.H., S.A.M., M.S.S., B.M.S., D.A.M.); South Australian Health and Research Institute, Flinders University and Medical Centre, Adelaide (P.E.A.); Division of Cardiovascular Diseases, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago (R.C.); Department of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (G.M.D.F.); Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion, Haifa, Israel (B.S.L.); and IV Divisione Cardiologia, Azienda Ospedaliera Niguarda Ca' Granda, Milan, Italy (P.A.M.).
Background: Patients with stable ischemic heart disease and previous myocardial infarction (MI) vary in their risk for recurrent cardiovascular events. Atherothrombotic risk assessment may be useful to identify high-risk patients who have the greatest potential to benefit from more intensive secondary preventive therapy such as treatment with vorapaxar.
Methods: We identified independent clinical indicators of atherothrombotic risk among 8598 stable, placebo-treated patients with a previous MI followed up for 2.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
N Engl J Med
June 2015
From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, and Harvard Medical School, Boston (C.P.C., R.P.G., A.M., K.I., E.A.B., S.D.W., E.B.); Duke Clinical Research Institute (DCRI), Durham, NC (M.A.B., J.A.W., C.R., R.M.C.); Montreal Heart Institute, Montreal (P.T.); Vivantes Neukölln Medical Center, Berlin (H.D.); Lady Davis Carmel Medical Center, Haifa, Israel (B.S.L.); Canisius-Wilhelmina Ziekenhuis, Nijmegen (T.O.O.), and the Netherlands Leiden University Medical Center, Leiden (J.W.J.) - both in the Netherlands; Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy (G.M.D.F.); National Institute of Cardiology, Warsaw, Poland (W.R.); and Merck, Kenilworth, NJ (P.D.L., A.M.T., T.A.M.).
Background: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.
Methods: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.
Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation.
Circulation
June 2015
From Department of Cardiology and Cardiovascular Clinical Research Center (G.M.D.F., V.D.) and Division of Vascular Surgery (A.O.), Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Italy (G.M.D.T., V.D., C.S., L.C.); Center for Cardiac Arrhythmias of Genetic Origin, IRCCS Istituto Auxologico Italiano, Milano, Italy (C.S., L.C., P.J.S.); Departments of Medicine, Pediatrics, and Molecular Pharmacology & Experimental Therapeutics, Divisions of Cardiovascular Diseases and Pediatric Cardiology, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN (J.M.B., C.R.M., M.J.A.); Cardiac Arrhythmia Service, Department of Cardiology, Children's Hospital, Boston, MA (D.J.A.); Division of Cardiology, Children's National Heart Institute, George Washington University, Washington, DC (C.I.B.); Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany (L.C.); Department of Cardiology, The Royal Children's Hospital, Murdoch Children's Research Institute and Melbourne University, Melbourne, Australia (A.M.D.); Heart Institute, Leviev Heart Center, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel (M.E.); Department of Clinical Cardiology and Molecular Genetics, National Center for Preventive Medicine, Ministry of Healthcare, Russian Federation, Moscow, Russia (M.K.); Bruce Rappaport Faculty of Medicine; Technion, Haifa, Israel (A.K.); Division of Cardiology, University of British Columbia, Vancouver, Canada (A.D.K.); AP-HP, Hôpital Bichat, Service de Cardiologie et Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France (A.L.); Université Paris Diderot, Sorbonne Paris Cité, Paris, France (A.L.); Heart Centre AMC, Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands (L.O.N., A.A.M.W.); Department of Pediatric Cardiology and Intensive Care Medicine, University Hospital, Georg-August-University,
Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder causing life-threatening arrhythmias whenever sympathetic activity increases. β-Βlockers are the mainstay of therapy; when they fail, implantable cardioverter-defibrillators (ICDs) are used but often cause multiple shocks. Preliminary results with flecainide appear encouraging.
View Article and Find Full Text PDFAutonomic modulation for the management of patients with chronic heart failure.
Circ Heart Fail
May 2015
From the Center for Cardiac Arrhythmias of Genetic Origin, IRCCS Istituto Auxologico Italiano, Milan, Italy (P.J.S.); Department of Cardiology, Fondazione "Salvatore Maugeri", IRCCS Istituto Scientifico di Montescano, Montescano, Pavia, Italy (M.T.L.R.); Department of Cardiology and Cardiovascular Clinical Research Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (G.M.D.F.); Department of Molecular Medicine, University of Pavia, Pavia, Italy (G.M.D.F.); and Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St Louis, MO (D.L.M.).
Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure.
Hypertension
January 2015
From the Department of Cardiology, INSERM, Center d'Investigation Clinique 9501 and Unité 961, Center Hospitalier Universitaire, Nancy University, Université de Lorraine, Nancy, France (F.Z.); Departments of Pharmacy Practice and Clinical Research, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC (W.G.S.); Klinik für Innere Medizin III, Universtitätsklinikum des Saarlandes, Homburg/Saar, Germany (F.M.); Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, MA (F.M.); ASH Comprehensive Hypertension Center, The University of Chicago Medicine, IL (G.L.B.); Oslo University Hospital, Ullevaal, Institute for Clinical Medicine, University of Oslo, Oslo, Norway (S.E.K.); CVRx, Inc, Minneapolis, MN (R.S.K., N.Y.); Department of Nephrology, Medizinische Hochschule Hannover, Hannover, Germany (H.H.); Department of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (G.M.D.F.); Department of Medicine, Division of Cardiology, Montefiore-Einstein Medical Center, Bronx, NY (I.L.P.); Boston Scientific Corporation, St. Paul, MN (K.S.); Université Paris Descartes, Paris, France (M.A.); Assistance Publique, Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris, France (M.A.); and Inserm CIC 9201, Paris, France (M.A.).